Pharmaceuticals giant Merck is seeking a patent for a way to use blockchain in order to track goods as they move through the supply chain.
Published last Thursday and submitted in December 2016, the patent application outlines a method by which a blockchain could be used to store information about a physical object – in this case, a single product – and receive updates as it moves onward from its point of origin. That distributed network could then be used to store information verifying the authenticity of the item.
In other words, the main point here is anti-counterfeiting. Merck already maintains internal processes for eliminating fake goods that move through its systems, and the proposed patent seems as if it would fit into those wider efforts.
Merck notes in its filing that the technology "enables a secure, reliable storage of the reading results with very high data integrity, such that it is essentially impossible to manipulate or erase or otherwise taper [sic] with or lose such data, e.g. due to unintended or deliberate deletion or due to data corruption."
The pharmaceuritcals firm goes on to explain:
Whether Merck will move to "put pills on the blockchain" remains to be seen, but the company has pursued a number of initiatives to date within the technology space.
Merck image via Katherine Welles / Shutterstock
The leader in news and information on cryptocurrency, digital assets and the future of money, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups. As part of their compensation, certain CoinDesk employees, including editorial employees, may receive exposure to DCG equity in the form of stock appreciation rights, which vest over a multi-year period. CoinDesk journalists are not allowed to purchase stock outright in DCG.